期刊文献+

(S)-苹果酸卡赞替尼的合成 被引量:3

Synthesis of Cabozantinib(S)-Malate
原文传递
导出
摘要 3,4-二甲氧基苯胺(2)与5-(甲氧基亚甲基)-2,2-二甲基-1,3-二噁烷-4,6-二酮发生取代反应,再经环合、氯代,与对硝基苯酚反应制得6,7-二甲氧基-4-(4-硝基苯氧基)喹啉,再经过Pd/C-H2还原、酰化、成盐反应得到抗肿瘤药(S)-苹果酸卡赞替尼,总收率约44%(以2计)。 Cabozantinib (S) -malate, an antineoplastic agent, was synthesized from 3,4-dimethoxyaniline (2) by substitution with 5-(methoxymethylene)-2,2-dimethyl-l,3-dioxane-4,6-dione, cyclization, chlorination and nucleophilic substitution with p-nitrophenol to give 6,7-dimethoxy-4-(4-nitrophenoxy)quinoline, which was subjected to Pd/C-H2 reduction, acylation and salt forming reaction with an overall yield of about 44 % (based on 2).
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第3期207-210,共4页 Chinese Journal of Pharmaceuticals
关键词 (S)-苹果酸卡赞替尼 抗肿瘤药物 酪氨酸激酶抑制剂 合成 cabozantinib (S) -malLate antimmor agent tyrosine kinase inhibitor synthesis
  • 相关文献

参考文献9

  • 1Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth [J]. Mol Cancer Ther, 2011, 10(12) : 2297-2308.
  • 2林欢,杨露璐.2011年临床肿瘤学重大进展——美国临床肿瘤学会年度报告[J].徇证医学,2012,1(12):6-22.
  • 3Bannen LC, Chan DS, Forsyth TP, et al. Methods of using C-Met modulators: US, 20120070368 [P]. 2012-03-22.
  • 4Wilson JA. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds: WO, 2012109510 [PJ. 2012-08-16.
  • 5Bannen LC, Chart DS, Chen J, et al. C-Met modulators and methods of use: WO, 2005030140 [P]. 2005-04-07.
  • 6Madrid PB, Sherrill J, Liou AP, et al. Synthesis of ring- substituded 4-aminoquinolines and evaluation of their antimalarial activities [J]. Bioorg Med Chem Lett, 2005, 15(4): 1015-1018.
  • 7Boyer CD, Liang SX. Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders: WO, 2008048375 [P]. 2008-04-24.
  • 8Norwich Pharrna Co.. Pharmaceutical composition containing quinoline compounds: GB, 942524 EP]. 1963-11-20.
  • 9Thomas AP, Hennequin LFA, Pie P, et al. Quinoline derivatives inhibiting the effect of growth factors such as VEGF: US, 6809097 [P]. 2004-10-26.

同被引文献21

  • 1Yakes FM,Chen J,Tan J,et al.Cabozantinib(XL184),a novel MET and VEGFR2 inhibitor,simultaneously suppresses metastasis,angiogenesis,and tumor growth[J].Mol Cancer Ther,2011,10(12):2298-2308.
  • 2Rossella E,Martin JS,Stefan PM,et al.Cabozantinib in progressive medullary thyroid cancer[J].J Clin Oncol,2013,31(29):3618-3620.
  • 3Pinto A.Cabozantinib:a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma[J].Cancer Chemoth Pharm,2014,73(2):219-222.
  • 4Brown SC,Lamb P,Gallagher WP,et al.Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl-N′-(4-fluorophenyl) cyclopropane-1-dicarboxamide,and crystalline forms therof for the treatment:WO,2010/083414[P].2010-07-22.
  • 5Wilson JA.Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds:WO,2012/109510[P].2012-08-16.
  • 6Kubo K,Shimizu T,Ohyama S,et al.A novel series of 4-phenoxyquinolines:potent and highly selective inhibitors of PDGF receptor autophosphorylation[J].Bioorg Med Chem Lett,1997,7(23):2935-2940.
  • 7Kubo K,Shimizu T,Ohyama S,et al.Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors:synthesis,structure-activity relationships,and antitumor activities of N-phenyl-N′-{4-(4-quinolyloxy) phenyl} ureas[J].JMedChem,2005,48(5):1359-1366.
  • 8府莹,张庆文.盐酸替沃扎尼一水合物的合成[J].中国新药杂志,2013,22(1):26-29. 被引量:4
  • 9郑希元,姜汉杰,蒲小平.抗甲状腺髓样癌新药卡博替尼[J].中国新药杂志,2013,22(17):1990-1993. 被引量:7
  • 10陈卓,于刚,张庆文.(S)-苹果酸卡赞替尼的合成[J].中国医药工业杂志,2014,45(5):401-403. 被引量:2

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部